EyePoint Pharmaceuticals, Inc.
Watertown, Massachusetts, United States · Biotechnology, Healthcare, Health Care
EyePoint Pharmaceuticals, Inc. is committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases.
Key facts
- Headquarters
- Watertown, Massachusetts, United States
- Employees
- Unknown
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (EYPT)
- Website
- eyepointpharma.com
- Company page
Recent activity at EyePoint Pharmaceuticals, Inc.
- : SEC 8-K (8.01): On September 10, 2026, EyePoint, Inc. provided an update by posting a new investor presentation on its official website, which may include important strategic and financial information relevant for investors. This presentation could contain insights into the company’s performance, future outlook, or updates on ongoing projects. The event's date aligns with the filing date, confirming the relevance and recency of the information provided. This disclosure is aimed at keeping shareholders informed and may affect investor sentiment and stock performance.
- : EyePoint Appoints Tarek S. Hassan as Senior Vice President, Chief Strategic Science Officer
- : EyePoint Appoints Michael Campbell as Chief Commercial Officer
- : SEC 8-K (1.01): On October 14, 2025, EyePoint Pharmaceuticals, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC, Jefferies LLC, Citigroup Global Markets Inc., and Guggenheim Securities, LLC, representing the underwriters for a public offering of 11,000,000 shares of the Company's common stock at a public price of $12.00 per share. Additionally, pre-funded warrants to purchase 1,500,000 shares of Common Stock were issued at a price of $11.999 each, reflecting the exercise price of $0.001 per share. This agreement is aimed at raising capital through the sale of equity into the market, thereby impacting the company's financial stability and growth potential.
- : EyePoint Pharmaceuticals announces first patient dosed in the global Phase 3 clinical trial of DURAVYU for the treatment of wet age-related macular degeneration.
- : EyePoint Pharmaceuticals Grants Non-Statutory Stock Options to New Employees
- : EyePoint Pharmaceuticals, Inc. Appoints Isabelle Lefebvre as Chief Regulatory Officer
- : EyePoint Pharmaceuticals Appoints Ramiro Ribeiro as Chief Medical Officer
- : EyePoint Pharmaceuticals Announces Chief Executive Officer
- : EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Apr 2018 | Venture | $9.5M |
| Apr 2018 | Seed | $450K |
Leadership
- Ronald Eastman, Director
- Kristine Peterson, Director
- Jay Duker, Director
- James Barry, Director
- Douglas Godshall, Director
- Michael Rogers, Director
- David Mazzo, Director
- Nancy Lurker, Executive Officer, Director
- Michael Campbell, Chief Commercial Officer
- Tarek S. Hassan, M.D., Senior Vice President
- Michael Campbell, Chief Commercial Officer
- Isabelle Lefebvre, Chief Regulatory Officer
Verified email and direct lines for EyePoint Pharmaceuticals, Inc.’s decision-makers are on Fundz. See plans
Employee benefit plans
EyePoint Pharmaceuticals, Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
EyePoint Pharmaceuticals, Inc. in the news
- A rival goes after Ocular Therapeutix on eve of pivotal readout on eye treatment - STAT (Feb 05, 2026)
- EyePoint Pharmaceuticals doses first patient in Phase 2 VERONA Clinical Trial of EYP-1901 for treatment of DME - Ophthalmology Times (Jan 10, 2024)
- EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky - PR Newswire (Aug 26, 2026)
- EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from - MultiVu (Nov 13, 2021)
- EyePoint Pharmaceuticals falls short of primary endpoint for Phase 2 PAVIA Trial for NPDR - Optometry Times (May 09, 2024)
- EyePoint Pharmaceuticals reports positive 16-week interim results from Phase 2 VERONA trial of Duravyu for diabetic macular edema | Eye Care Network - Modern Retina - Ophthalmology Times (Oct 28, 2024)
- EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD - PR Newswire (Feb 12, 2022)
- EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9% - MultiVu (Jul 08, 2019)
Companies similar to EyePoint Pharmaceuticals, Inc.
- AIM ImmunoTech · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Olema Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- AbbVie Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Reneo Pharmaceuticals, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
- Imago BioSciences, Inc. · Biotechnology, Healthcare, Health Care, Pharmaceutical, Therapeutics
About EyePoint Pharmaceuticals, Inc.: questions and answers
What does EyePoint Pharmaceuticals, Inc. do?
EyePoint Pharmaceuticals, Inc. is committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases.
Where is EyePoint Pharmaceuticals, Inc. headquartered?
EyePoint Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts, United States.
Has EyePoint Pharmaceuticals, Inc. raised funding?
Yes. Fundz has recorded 2 funding events for EyePoint Pharmaceuticals, Inc.. The most recent, $9.5M, was in Apr 2018.
Who leads EyePoint Pharmaceuticals, Inc.?
Tarek S. Hassan, M.D. is a Senior Vice President at EyePoint Pharmaceuticals, Inc..
What is the latest news on EyePoint Pharmaceuticals, Inc.?
On Sep 10, 2026, SEC 8-K (8.01): On September 10, 2026, EyePoint, Inc. provided an update by posting a new investor presentation on its official website, which may include important strategic and financial information relevant for investors. This presentation could contain insights into the company’s performance, fu
Is EyePoint Pharmaceuticals, Inc. a public company?
Yes. EyePoint Pharmaceuticals, Inc. is publicly traded under the ticker EYPT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy